Anixa Biosciences (NASDAQ:ANIX) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Anixa Biosciences (NASDAQ:ANIX) issued its quarterly earnings data on Friday. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02, Zacks reports.

Anixa Biosciences Price Performance

Shares of Anixa Biosciences stock opened at $2.25 on Friday. The firm has a market cap of $72.40 million, a price-to-earnings ratio of -5.77 and a beta of 0.90. Anixa Biosciences has a 52-week low of $2.14 and a 52-week high of $5.13. The company’s 50-day simple moving average is $2.94 and its 200-day simple moving average is $3.02.

Analysts Set New Price Targets

Several research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.